Merck & Co., Inc. (NYSE:MRK – Get Free Report) was downgraded by equities research analysts at Royal Bank Of Canada from an “outperform” rating to a “sector perform” rating in a research report issued on Thursday. They presently have a $150.00 target price on the stock. Royal Bank Of Canada’s target price would suggest a potential downside of 1.45% from the stock’s current price.
A number of other equities research analysts also recently commented on MRK. Weiss Ratings downgraded Merck & Co., Inc. from a “hold (c)” rating to a “hold (c-)” rating in a research report on Tuesday, August 11th. Daiwa Securities Group raised Merck & Co., Inc. from a “neutral” rating to an “outperform” rating and set a $143.00 target price on the stock in a research report on Wednesday, August 12th. Guggenheim lifted their target price on Merck & Co., Inc. from $145.00 to $146.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Citigroup assumed coverage on Merck & Co., Inc. in a research report on Wednesday, May 6th. They set a “neutral” rating and a $125.00 price target for the company. Finally, Morgan Stanley upgraded Merck & Co., Inc. from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $116.00 to $179.00 in a research note on Thursday. Fifteen equities research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat.com, Merck & Co., Inc. currently has an average rating of “Moderate Buy” and a consensus price target of $139.20.
Read Our Latest Stock Analysis on MRK
Merck & Co., Inc. Stock Performance
Merck & Co., Inc. (NYSE:MRK – Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The business had revenue of $16.61 billion for the quarter, compared to the consensus estimate of $16.37 billion. During the same quarter in the prior year, the firm posted $2.13 earnings per share. The company’s quarterly revenue was up 5.1% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, equities analysts anticipate that Merck & Co., Inc. will post 2.77 earnings per share for the current year.
Insiders Place Their Bets
In related news, EVP Richard R. Deluca sold 20,784 shares of the firm’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $130.43, for a total transaction of $2,710,857.12. Following the completion of the sale, the executive vice president directly owned 134,703 shares of the company’s stock, valued at approximately $17,569,312.29. This trade represents a 13.37% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP David Michael Williams sold 52,847 shares of Merck & Co., Inc. stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $128.77, for a total transaction of $6,805,108.19. Following the sale, the executive vice president directly owned 31,716 shares in the company, valued at $4,084,069.32. This trade represents a 62.49% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 228,238 shares of company stock valued at $29,977,783. Corporate insiders own 0.17% of the company’s stock.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the business. Brighton Jones LLC raised its holdings in Merck & Co., Inc. by 29.5% in the fourth quarter. Brighton Jones LLC now owns 38,278 shares of the company’s stock valued at $3,808,000 after acquiring an additional 8,710 shares in the last quarter. Sivia Capital Partners LLC grew its holdings in Merck & Co., Inc. by 52.2% during the 2nd quarter. Sivia Capital Partners LLC now owns 11,494 shares of the company’s stock worth $910,000 after acquiring an additional 3,941 shares in the last quarter. Diversify Advisory Services LLC increased its position in shares of Merck & Co., Inc. by 94.1% in the 2nd quarter. Diversify Advisory Services LLC now owns 32,256 shares of the company’s stock worth $2,590,000 after purchasing an additional 15,636 shares during the last quarter. Diversify Wealth Management LLC increased its position in shares of Merck & Co., Inc. by 22.2% in the 2nd quarter. Diversify Wealth Management LLC now owns 38,031 shares of the company’s stock worth $3,054,000 after purchasing an additional 6,897 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Merck & Co., Inc. by 111.7% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 681,128 shares of the company’s stock worth $53,918,000 after purchasing an additional 359,356 shares during the last quarter. Hedge funds and other institutional investors own 76.07% of the company’s stock.
Merck & Co., Inc. News Roundup
Here are the key news stories impacting Merck & Co., Inc. this week:
- Positive Sentiment: The combination of Moderna’s individualized vaccine, intismeran, and Keytruda significantly extended the time high-risk melanoma patients remained free of recurrence and reduced the risk of cancer spreading compared with Keytruda alone. The result is viewed as the first positive late-stage validation of a personalized mRNA cancer vaccine. Merck, Moderna say melanoma skin cancer vaccine meets goals in large trial
- Positive Sentiment: The data strengthen Merck’s oncology pipeline and could help offset concerns about the expected expiration of Keytruda’s patent later this decade. The companies are also studying similar vaccine approaches in lung, pancreatic, breast and other cancers, potentially expanding the commercial opportunity if regulators approve the treatment; approval is targeted for 2027. Moderna, Merck breakthrough could usher in wave of cancer vaccines
- Positive Sentiment: Investor enthusiasm was reflected in unusually heavy options activity, with 68,587 Merck call options purchased—about 188% above typical daily volume—suggesting increased bullish speculation, though options activity is not a fundamental performance measure.
- Neutral Sentiment: Broader bond-market relief supported interest-rate-sensitive equities and healthcare stocks, providing a favorable market backdrop for MRK. Stock Market Today, Aug. 19
- Negative Sentiment: Jefferies downgraded MRK from “strong buy” to “hold.” The call could limit further upside and reflects a more cautious analyst view after the stock’s strong run toward its 52-week high, although the firm’s specific rationale was not provided.
Merck & Co., Inc. Company Profile
Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.
Founded in the late 19th century as the U.S.
Featured Stories
- Five stocks we like better than Merck & Co., Inc.
- Diamondback Hits a Milestone at Just the Right Time
- Analog Devices’ AI Pivot Could Push Shares to Fresh Highs
- One Platform, Every Ailment: Hinge Health’s Gamble
- Bloom Energy’s AI Surge Meets a Valuation Reality Check
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
